- Home
- ORGN vs ALEC Comparison
ORGN vs ALEC Comparison
Compare ORGN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- ALEC
- Stock Information
- Founded
- ORGN 2008
- ALEC 2013
- Country
- ORGN United States
- ALEC United States
- Employees
- ORGN N/A
- ALEC N/A
- Industry
- ORGN Major Chemicals
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORGN Industrials
- ALEC Health Care
- Exchange
- ORGN Nasdaq
- ALEC Nasdaq
- Market Cap
- ORGN 199.7M
- ALEC 232.6M
- IPO Year
- ORGN N/A
- ALEC 2019
- Fundamental
- Price
- ORGN $1.01
- ALEC $1.86
- Analyst Decision
- ORGN Strong Buy
- ALEC Buy
- Analyst Count
- ORGN 1
- ALEC 6
- Target Price
- ORGN $3.00
- ALEC $11.75
- AVG Volume (30 Days)
- ORGN 1.2M
- ALEC 2.3M
- Earning Date
- ORGN 11-14-2024
- ALEC 11-06-2024
- Dividend Yield
- ORGN N/A
- ALEC N/A
- EPS Growth
- ORGN N/A
- ALEC N/A
- EPS
- ORGN N/A
- ALEC N/A
- Revenue
- ORGN $35,123,000.00
- ALEC $61,508,000.00
- Revenue This Year
- ORGN $10.27
- ALEC N/A
- Revenue Next Year
- ORGN $80.25
- ALEC $71.71
- P/E Ratio
- ORGN N/A
- ALEC N/A
- Revenue Growth
- ORGN 123.12
- ALEC N/A
- 52 Week Low
- ORGN $0.44
- ALEC $1.73
- 52 Week High
- ORGN $1.90
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- ORGN 30.46
- ALEC 22.54
- Support Level
- ORGN $0.95
- ALEC $1.74
- Resistance Level
- ORGN $1.28
- ALEC $2.50
- Average True Range (ATR)
- ORGN 0.07
- ALEC 0.16
- MACD
- ORGN -0.02
- ALEC 0.03
- Stochastic Oscillator
- ORGN 3.12
- ALEC 2.37
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.